AI + EXCLUSIVE DATA

AI tracks executive moves from sources others don't have

Our proprietary AI analyzes exclusive hiring data to find decision-makers actively evaluating solutions like yours.

10-25 executive leads daily • Direct contact info • First 90 days targeting

Start with:

✓Flexible Plans • $39/mo or $29/mo annual

✓AI + proprietary hiring database

✓Executive contact details included

INDUSTRY FIRST

Huyabio International Appoints Paul Spreen As Chief Business Officer

Mar 18, 2025•5 months ago

Position

Chief Business Officer

Company

HUYABIO International

Paul Spreen

San DiegoBiopharmaBiotechnology

Description

HUYABIO International has appointed Paul Spreen as Chief Business Officer. Dr. Mireille Gillings, President, CEO & Executive Chair at HUYABIO, expressed delight in welcoming Paul Spreen to the executive team, citing his global management and business development expertise as invaluable.

Company Information

Company

HUYABIO International

Location

San Diego, California, United States

About

HUYABIO is the leader in accelerating the global development of novel biopharmaceutical product opportunities originating in China enabling faster, more cost-effective and lower-risk drug development in the global markets. Through extensive collaboration with biopharmaceutical, academic and commercial organizations, it has built the largest China-sourced compound portfolio covering all therapeutic areas. With offices in the US, Japan, South Korea, Canada, Ireland and eight strategic locations across China, the Company has become a partner of choice to accelerate product development and maximize value globally.

Company News

(3 articles)

Tue, 30 Nov 2021 08:00:00 GMT

Jemincare Announces the Exclusive License of the Kras Inhibitor to HUYABIO - PR Newswire

Thu, 06 Jan 2022 08:00:00 GMT

HBI-8000, HUYABIO Lead Clinical Program, Is a Selective Histone Deacetylase Inhibitor With Therapeutic Benefits in Leukemia and in Solid Tumors - Frontiers

Tue, 30 Nov 2021 08:00:00 GMT

HUYABIO International Receives Regulatory Approval For Hiyasta® Monotherapy Of Peripheral T-Cell Lymphoma In Japan - PR Newswire

FundzWatch™ Score

Low Activity

1 total signals

Buyer Intent Analysis

Get personalized insights on buying likelihood

Related People

Executive Insights

Based on hiring data

New executive impact window

87% of new executives make significant technology decisions within first 100 days

Budget influence

C-level executives control 73% of technology spending decisions

Transformation catalyst

65% of new senior hires launch digital transformation initiatives

Vendor review timeline

New executives typically review existing vendors within 6 months